<DOC>
	<DOCNO>NCT01456676</DOCNO>
	<brief_summary>The purpose study determine feasibility administer combination nilotinib LDE225 patient chronic accelerated phase chronic myeloid leukemia establish maximum tolerate dose ( MTD ) and/or recommend Phase II dose level ( RP2D ) LDE225 combination nilotinib .</brief_summary>
	<brief_title>Nilotinib LDE225 Treatment Chronic Accelerated Phase Myeloid Leukemia Patients Who Developed Resistance Prior Therapy</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<criteria>1 . Philadelphia chromosome positive ( Ph+ ) CML chronic phase ( CP ) accelerate phase ( AP ) resistance least one prior BCRABL target TKI 2 . Documented chronic phase CML 3 . Adequate end organ function 4 . Female patient childbearing potential must negative serum pregnancy test must use highly effective method contraception . Male patient female partner childbearing potential must use condom . 1 . Impaired cardiac function 2 . Severe and/or uncontrolled concurrent disease opinion investigator could cause unacceptable safety risk compromise compliance protocol 3 . History acute pancreatitis within 1 year study entry past medical history chronic pancreatitis 4 . Patients actively receive therapy strong CYP3A4 inhibitor and/or inducer , treatment either discontinue switched different medication prior enter study 5 . Patients currently receive treatment medication potential prolong QT interval treatment either safely discontinue switch different medication prior start study drug . 6 . Previously document BCRABL Y253H , E255K/V , T315I F359C/V mutation Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>LDE225</keyword>
	<keyword>nilotinib</keyword>
	<keyword>Chronic myeloid leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>Philadelphia positive</keyword>
	<keyword>Ph+</keyword>
	<keyword>resistant</keyword>
	<keyword>Resistant Philadelphia chromosome positive chronic myeloid leukemia ( Ph+ CML ) chronic phase ( CP )</keyword>
</DOC>